Recently, Vitro Diagnostics (VODG) made it to our watchlist and we were pretty excited to share the story with you. The company, with a strong history in the development of stem cells for use in therapeutic options, as a potential treatment for critically ill COVID-19 patients that seems to be overwhelmingly promising.
We’re glad we started watching when we did. On Tuesday, Vitro announced positive results from a critically ill COVID-19 patient that was treated with its AlloRx Stem Cells. The data was overwhelmingly positive, with the AlloRx Stem Cells essentially saving the patient’s life. The success rested on Vitro’s unique proprietary knowledge and capabilities achieved over many years of research and refinement of utilizing stem cell therapy across a wide range of applications.
VODG Rocketed After Announcing Positive Results
On Tuesday Vitro Diagnostics announced the results of treatment of a critically ill COVID-19 patient with its AlloRx Stem Cells. The results proved to be extraordinarily positive. However, before we get to the results, the state of the patient before treatment with the stem cell product should be addressed.
The patient was admitted to the ER after displaying classic COVID-19 symptoms. Unfortunately, prior to the patient’s admission, he had several comorbidities. The patient was then admitted to the intensive care unit and intubated. To the dismay of the hospital staff his condition continued to degrade despite a variety of treatments offered by the ICU team.
His worsening condition led to the beginning signs of kidney and liver failure. Ultimately, the failure of these key organs led to the use of dialysis. Moreover, the patient experienced sepsis and stroke while under the care of physicians in the ICU and spent more than two and a half months in a coma ; the prognosis was about as grim as it gets.
With the patient perceived to be near death, he was provided with AlloRx Stem Cells developed by VODG, which quickly led to a resolution of the multiple organ failure. The treatment also led to a recovery from the coma, and restoration of neurological, pulmonary, liver and renal function.
Soon, the patient was removed from assisted respiration and dialysis. Today, he is eating, drinking, speaking and has regained motor function. Moreover, key measures of inflammation that rose throughout treatment prior to the use of AlloRx Stem Cells, quickly returned to normal levels after AlloRx treatment.
While the patient is currently undergoing physical therapy to recover from the stroke he experienced while in ICU, he has been discharged from the ICU and no longer faces serious symptoms of COVID-19.
The protocols applied by the VODG team and associated AlloRx stem cell formulations are unique to the Company and Vitro believes it has a leading position particularly in addressing severe, near death, COVID-19 patients.
The use of the AlloRx Stem Cells in this patient was authorized by the FDA in an emergency use setting. The EUA was granted to GIOSTAR, Vitro’s partner in the development of AlloRx Stem Cells, as a therapeutic agent for patients with severe COVID-19.
In a statement, Dr. Anand Srivastava, MS, PhD, Chairman and CSO at GIOSTAR, had the following to offer:
“COVID-19 infection triggers the spectrum of inflammatory cytokines, which results in severe COVID-19 induced pneumonia and acute respiratory distress syndrome (ARDS), followed by multiple organ failure. Utilizing the natural immunomodulatory character of AlloRx Stem Cells may be one of the best ways to neutralize COVID-19 induced inflammatory cytokines actions on the lung and other organs to rescue the patients suffering from COVID-19 infection.
The above statement was followed up by Dr. Jack Zamora, MD, Chief Medical Advisor at VODG. Here’s what he had to say:
“The miraculous recovery of our first critically ill COVID-19 patient using AlloRx Stem Cells brings great home in these troubling times. We continue with our FDA IND application with even greater hope of delivering a promising treatment to US patients, and through GIOSTAR, we have reached out to various ministries of Health Worldwide with this promising news.”
Finally, Dr. Jim Musick, CEO at VODG, said:
“We are pleased to have achieved this milestone that was based on thorough understanding of the science of stem cell biology. While regeneration of destroyed cells is a common effect of stem cell therapy, stem cells also regenerate damaged cells by various regenerative processes that restore normal organ function. The results of this case support the further study of AlloRx Stem Cell Therapy for COVID-19 patients and other conditions characterized by acute respiratory distress that are ultimately related to the inflammatory cytokine cascade that is neutralized by AlloRx Stem Cells. Our therapy appears to have significant therapeutic application in treatment of multi-organ failure related to COVID-19 infections.”
This News Is Huge
The news released by Vitro Diagnostics is overwhelmingly positive. First and foremost, any time positive results are seen following the treatment of a critically ill patient with an experimental treatment option, there’s something to be excited about ahead. However, this goes far beyond that.
This particular patient was knocking on death’s door. Doctors had already tried everything they could to save his life to no avail. After providing standard of care therapy, the patient’s condition continued to worsen. The, AlloRx Stem Cell Therapy worked. There’s no other way to say it.
The patient that is now able to hug family members, talk to friends, eat his favorite meal, and enjoy life. That is incredible. Moreover, it’s a notch on the belt of VODG as we take one step toward victory in the fight against COVID-19.
As the United States works to reopen, case counts of COVID-19 are increasing again. As this continues, it is becoming increasingly clear that in order to make it back to life as usual, we need vaccine and treatment options.
At the moment, there are a massive number of biotechnology companies working toward a vaccine, but few are actually working on a treatment. Of the few working on a treatment, even fewer have anything tangible, and I can’t even think of a handful that actually have something that has shown promise in the treatment of a real COVID-19 patient.
This creates an interesting opportunity. The truth of the matter is VODG is a very small company, trading with a market cap of around $30 million. However, it’s playing a game with a few goliath’s on the field. At the same time, the company has found a way to manufacture its stem cell therapy at a fraction of the cost generally seen in the space. It is also worth noting that Vitro’s proof of capabilities in utilizing proprietary stem cell treatments to address critical covid patients, creates enthusiasm towards the expectation that Vitro has the potential of solving other intractable conditions/diseases utilizing stem cell techniques as it has in alleviating the debilitating effects of Multiple Sclerosis.
With an incredibly low market cap, one of the least cash-intensive business models I’ve seen in biotech, and a treatment that is proving to be effective in critically ill COVID-19 patients, I see this going one of two ways. Either VODG will continue to develop and eventually bring its AlloRx Stem Cell Therapy product to fruition, or a savvy goliath in biotech will see value in the incredible work the company has done, and take it over. Either way, it looks like great news ahead for the company and its investors!
[vc_row full_width=”stretch_row_content td-stretch-content”][vc_column][tdm_block_hero title_text=”R2V0JTIwRnJlZSUyMEFsZXJ0cw==” title_size=”tdm-title-bg” description=”Sm9pbiUyMG91ciUyMGZyZWUlMjBtYWlsaW5nJTIwbGlzdCUyMHRvJTIwcmVjZWl2ZSUyMHN0b2NrJTIwYWxlcnRzIQ==” button_text=”Join Our Mailing List Here” button_tdicon=”tdc-font-fa tdc-font-fa-chevron-right” button_url=”https://alphastocknews.us4.list-manage.com/subscribe?u=92a9c8ec6acba6727f3eff17d&id=b717e1440e” tds_button=”tds_button3″ button_size=”tdm-btn-lg” button_tdicon-1=”tdc-font-fa tdc-font-fa-search” tds_button-1=”tds_button3″ button_size-1=”tdm-btn-lg” block_width=”1200″ content_align_horizontal=”content-horiz-center” content_align_vertical=”content-vert-center” background=”eyJ0eXBlIjoiZ3JhZGllbnQiLCJjb2xvcjEiOiJyZ2JhKDIyLDExMiwxOTEsMC44NSkiLCJjb2xvcjIiOiJyZ2JhKDAsMCwwLDAuODUpIiwibWl4ZWRDb2xvcnMiOltdLCJjc3MiOiJiYWNrZ3JvdW5kOiAtd2Via2l0LWxpbmVhci1ncmFkaWVudCgwZGVnLHJnYmEoMCwwLDAsMC44NSkscmdiYSgyMiwxMTIsMTkxLDAuODUpKTtiYWNrZ3JvdW5kOiBsaW5lYXItZ3JhZGllbnQoMGRlZyxyZ2JhKDAsMCwwLDAuODUpLHJnYmEoMjIsMTEyLDE5MSwwLjg1KSk7IiwiY3NzUGFyYW1zIjoiMGRlZyxyZ2JhKDAsMCwwLDAuODUpLHJnYmEoMjIsMTEyLDE5MSwwLjg1KSJ9″][/vc_column][/vc_row]
This website/newsletter is owned, operated and edited by CNA Finance, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “CNA Finance” refers to CNA Finance, LLC. This webpage/newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to publish information and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners do not own any shares in stocks mentioned unless stated in page disclosures. If we own any shares we will list the information relevant to the stock and number of shares here. CNA Finance, parent company to Alpha Stock News, receives payment to publish content and promote publicly traded companies. Pursuant to an agreement between CNA Finance and Vitro Diagnostics, CNA Finance has been hired for a period beginning on 6/26/20 and ending on 8/26/20 to conduct digital advertising and marketing and publicly disseminate information about VODG via Websites and Email. We have an agreement and have been paid six thousand dollars via check to cover the cost of content production and publication for the first month. We expect to receive another payment of six thousand dollars to cover costs of services for month two.This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated digital outreach efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of digital outreach marketing, which may end as soon as the marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct and Vitro Diagnostics has not approved the content of this site. Furthermore, CNA Finance often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.